
Three patient advocacy groups are suing the Biden administration to challenge a federal regulation they say prevents patients from using drugmaker discounts like copay coupons.
Many drug manufacturers have set up so-called copay assistance programs designed to help with patients’ out-of-pocket costs for medications. But the groups — the HIV+Hepatitis Policy Institute, the Diabetes Leadership Council, and the Diabetes Patient Advocacy Coalition — claim that health insurers and pharmacy benefit managers have harmful policies that prevent those savings from actually reaching the patients. All three of the groups receive funding from drugmakers.